Evotec and Bayer Pharma have entered into a five-year, multi-target collaboration to develop three clinical candidates for the treatment of endometriosis. The companies will contribute drug targets and technology platforms and will share responsibility for early research and preclinical characterization of potential candidates. Bayer will be responsible for further development and commercialization. Evotec will receive $15 million upfront and is eligible for clinical and sales milestones totalin...